Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Africa, we supplied 60 000 vials of efl ornithine,<br />
100 000 vials of melarsoprol and 100 000 vials of<br />
pentamidine. Through the <strong>Aventis</strong> Foundation, we<br />
are working with the Nelson Mandela Foundation<br />
to combat tuberculosis in South Africa. Our human<br />
vaccines business continues to play a pivotal role in<br />
the Global Polio Eradication Initiative and has reinforced<br />
its commitment to strengthening vaccination<br />
systems in developing countries through EPIVAC.<br />
Pharma scenarios and the business case for<br />
sustainable healthcare<br />
The pharmaceutical industry is facing a set of issues<br />
that have the potential to signifi cantly alter<br />
the current business model. It is thus essential<br />
to anticipate key future developments through a<br />
strong, fl exible and durable policy framework. With<br />
this aim in mind, in <strong>2003</strong> we advanced the “Pharma<br />
Scenarios for Sustainable Healthcare” project. By describing<br />
the landscape in which future challenges,<br />
dilemmas and opportunities could play themselves<br />
out, the project aims to facilitate new ways of looking<br />
at established paradigms and develop strategies<br />
to position the company for a sustainable future.<br />
Addressing sustainability issues<br />
With a view to both effectively managing and<br />
shaping business-critical topics, we actively participate<br />
in industry and political dialogues. In <strong>2003</strong>,<br />
company experts continued to work closely with<br />
patient groups, legislators and non-governmental<br />
organizations on issues such as timely and equitable<br />
access to products and information for patients,<br />
restoring the competitiveness of the research-based<br />
pharmaceutical industry in Europe and intellectual<br />
property protection.<br />
To track and report annual progress on our environment,<br />
health and safety Journey to EHS Excellence,<br />
an annual scorecard was introduced in <strong>2003</strong>.<br />
>> 47